Recent Transactions

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

21-Dec-23
Undisclosed
Australia flag
Target: 

Exit of Homesafe Equity Release Joint Venture

Australia flag
Acquiror: 
Athy Pty Ltd

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

22-Aug-22
Pending
$92.9 million
Australia flag
Target: 

Australian Executor Trustees

Australia flag
Acquiror: 
Equity Trustees

Advising Equity Trustees, one of Australia’s leading specialist trustee companies, on the acquisition of Australian Executor Trustees from Insignia Financial

29-Jun-21
~$122 million
United Kingdom flag
Target: 

NobleOak Life

United States flag
Acquiror: 
Avant Mutual

Advised Avant Mutual, an Australian member-owned organization providing medical indemnity insurance products to healthcare practitioners, on the exit of its strategic stake in NobleOak Life via IPO

22-Jun-21
Pending
$8.2 billion
Australia flag
Target: 

Milton Corporation

Australia flag
Acquiror: 
Washington H. Soul Pattinson

Adviser to Milton Corporation on its merger with Washington H. Soul Pattinson effected via scheme of arrangement

28-Oct-20
Undisclosed
Australia flag
Target: 

Easton Investments Limited

Australia flag
Acquiror: 
HUB24 Limited

Advising HUB24 Limited (ASX: HUB), a leading specialist investment platform provider, on its proposed acquisition of up to 40% in Easton Investments Limited (ASX: EAS), a leading provider of wealth and accounting solutions. The transaction also included the divestment of HUB24’s subsidiary, Paragem, to Easton

10-Jun-20
$3.9 billion
Denmark flag
Target: 

Global collaboration agreement with Genmab A/S

United States flag
Acquiror: 
AbbVie, Inc

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

28-Oct-19
$NA
Brazil flag
Target: 

Supplier Participações

Brazil flag
Acquiror: 
Totvs

Advised Supplier Participações, the largest credit fintech company in Brazil and the first independent mover in supply chain financing, on the sale of a majority stake to Totvs, the leading provider of management software and related consulting services in Brazil

19-Jul-19
$NA
Brazil flag
Target: 

Ourinvest DTVM

Brazil flag
Acquiror: 
BTG Pactual

Advised the shareholders of Ourinvest DTVM, a leading Brazilian securities broker focused on providing high net-worth individuals custody, distribution and trading services, on the sale of an 80% stake to BTG Pactual, one of Brazil’s largest independent investment banking firms

29-May-19
$NA
Brazil flag
Target: 

Pravaler

Brazil flag
Acquiror: 
Itaú Unibanco

Advising IFC and Principia Capital Partners on the sale of their stakes in Pravaler, Brazil’s leading provider of student loans for college students, to Itaú Unibanco, Brazil’s largest financial institution

19-Mar-19
$NA
Australia flag
Target: 

BT Advice

Australia flag
Acquiror: 
Viridian Advisory

Advised Westpac, the third largest company in Australia by market capitalization, on its exit of BT Advice and the sale of select assets to Viridian Advisory

15-Mar-19
$NA
Brazil flag
Target: 

Blu Pagamentos

flag not available

Advised Blu Pagamentos, a high-growth Brazilian B2B cash management fintech firm, on the sale of a minority stake

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, US subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

12-Nov-18
$84 million
Australia flag
Target: 

AUB Group Limited

flag not available

Advised ASX-listed AUB Group, a leading insurance intermediary business operating a network of over 100 insurance brokers and underwriting agencies across Australia and New Zealand, on its fully underwritten entitlement offer to raise A$116mm

28-Sep-18
$NA
Australia flag
Target: 

Blue Sky Alternative Investments Limited

United States flag
Acquiror: 
Oaktree Capital Management L.P.

Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility

10-Sep-18
$100 million
Australia flag
Target: 

Montserrat Day Hospital Group

Australia flag
Acquiror: 
Primary Health Care

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

08-Aug-18
$538 million
Australia flag
Target: 

Suncorp Group Limited’s Australian Life Insurance Business

Japan flag
Acquiror: 
TAL

Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

11-Apr-14
$414 million
Australia flag
Target: 

Investec Bank (Australia) Limited

Australia flag
Acquiror: 
Bank of Queensland Limited

Advised Investec Bank (Australia) Limited on the sale of its Professional Finance and Asset Finance and Leasing businesses, its deposit book, and its Australian banking licence to Bank of Queensland Limited (“BOQ”). BOQ is a leading regional Australian bank which provides retail and business banking

05-Feb-14
$NA
Sweden flag
Target: 

Unfors Raysafe AB

United States flag
Acquiror: 
Fluke Biomedical Corporation

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

12-Jun-13
$893 million
Australia flag
Target: 

A$1.6bn non-core loan portfolio

United States flag
Acquiror: 
Goldman Sachs Group. Inc.

Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm

Pages

show all